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OBJECTIVES We sought to identify patient and hospital features associated with early glycoprotein (GP)
IIb/IIIa inhibitor therapy for non–ST-elevation (NSTE) myocardial infarction (MI) and to
relate this treatment to in-hospital outcomes.
BACKGROUND Glycoprotein IIb/IIIa inhibitors have improved outcomes in randomized trials of NSTE MI,
leading national treatment guidelines to recommend their use. Their actual use, safety, and
effectiveness have not been well characterized beyond trial populations.
METHODS We studied 60,770 patients with NSTE MI treated between July 2000 and July 2001 at 1,189
hospitals in a U.S. registry. Using logistic regression, we identified patient and hospital
features associated with GP IIb/IIIa inhibition within 24 h after presentation. We also
compared outcomes by early treatment versus no treatment after adjusting for patient and
hospital characteristics and treatment propensity.
RESULTS Only 25% of eligible patients received early GP IIb/IIIa therapy. Elderly patients, women,
minority patients, and those without private insurance received such therapy less often than
their counterparts. Treated patients had lower unadjusted in-hospital mortality (3.3% vs.
9.6%, p  0.0001) remaining significantly lower after adjustment for patient risk, treatment
propensity, and hospital characteristics (adjusted odds ratio, 0.88; 95% confidence interval,
0.79 to 0.97). Hospitals that adopted early GP IIb/IIIa inhibition more rapidly also had lower
adjusted mortality rates than those slower to adopt such therapy.
CONCLUSIONS Glycoprotein IIb/IIIa inhibitor therapy appears to be underused in early management of
NSTE MI patients. Because this therapy is associated with better outcomes, it represents a
target for quality improvement. (J Am Coll Cardiol 2003;42:45–53) © 2003 by the
American College of Cardiology Foundation
More than one million patients are hospitalized in the U.S.
each year for acute myocardial infarction (MI) (1). Most of
these patients will not have ST-segment elevation on their
initial electrocardiogram (ECG) and are classified as having
non–ST-elevation (NSTE) MI (2). The outcomes of pa-
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tients with NSTE MI can be improved if they are treated
acutely with antithrombotic agents, including aspirin and
heparin (3). Multiple randomized clinical trials have also
shown that intravenous platelet glycoprotein (GP) IIb/IIIa
receptor inhibitors significantly reduce the risk of death or
reinfarction in patients with NSTE MI (4). These findings
led the American College of Cardiology and American
Heart Association (ACC/AHA) in March 2000 to give a
class IA treatment recommendation for the use of GP
IIb/IIIa inhibitors, in addition to aspirin and heparin, in all
patients with positive cardiac markers (2).
Information concerning the use of GP IIb/IIIa inhibition
outside of selected clinical trial populations is limited. Are
these drugs being used in community practice in a manner
consistent with guideline recommendations? If not, where
are the gaps in use? Can the results from clinical trials be
generalized outside of trial populations? Are these drugs safe
and effective when used in an at-large patient population
that includes older and higher risk patients?
Using the National Registry of Myocardial Infarction
(NRMI) 4, we sought to characterize contemporary patterns
of GP IIb/IIIa inhibitor use in the early management of
patients with NSTE MI at 1,189 centers across the U.S.
We identified patient and hospital features associated with
a greater or lesser likelihood of receiving a GP IIb/IIIa
inhibitor within 24 h of hospital admission. We also
compared unadjusted and adjusted clinical outcomes be-
tween those receiving and not receiving early GP IIb/IIIa
inhibitor therapy. Finally, we assessed whether hospitals
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that had more completely adopted the ACC/AHA guide-
line recommendations for GP IIb/IIIa inhibitor use had
better risk-adjusted outcomes than did those who were
slower to adopt this practice.
METHODS
Data source. The NRMI is a voluntary, observational
study of hospitalized patients with a confirmed diagnosis of
acute MI. The fourth generation of data-collection, NRMI
4, began on July 1, 2000, and currently compiles data from
one in four acute-care hospitals in the U.S. Hospitals
participating in NRMI tend to be slightly larger, and have
more cardiac interventional facilities, than nonparticipating
hospitals. Characteristics of the NRMI data-collection pro-
cedures have been described in detail (5,6). Briefly, partic-
ipating hospitals are instructed to enroll consecutive MI
patients. Hospitals typically screen for MI based on dis-
charge diagnosis code of 410.x1 according to the ninth
revision of International Classification of Disease (7). The
clinical diagnosis of MI is then confirmed based on one or
more of the following: 1) total creatine kinase (CK) or
CK-MB level at least twice the upper limit of normal; 2)
ECG evidence of acute MI; 3) enzymatic, scintigraphic, or
other evidence of MI. All data are abstracted via chart
review at the hospital by a trained clinical data abstractor
using standardized definitions.
Study population. We included patients enrolled between
July 1, 2000, and July 31, 2001. From this population, we
excluded patients with ST-segment elevation or new
bundle-branch block on the baseline ECG, those treated
with fibrinolytic therapy, and those who had normal levels
of serum cardiac markers. We also excluded those who were
transferred out of an NRMI hospital (incomplete follow-
up) and those who were transferred to an NRMI hospital
24 h after MI onset (nonacute patients). Finally, we
excluded those with potential contraindications for intrave-
nous GP IIb/IIIa inhibitors, including active bleeding,
recent surgery, malignancy, uncontrolled hypertension,
traumatic cardiopulmonary resuscitation, prior stroke, cre-
atinine  2.5 mg/dl, or known bleeding disorder, and those
for whom the use or timing of GP IIb/IIIa inhibition was
unknown.
Study variables and definitions. The NRMI 4 case report
form contains demographic and clinical information, in-
cluding patient age, race, gender, insurance status, medical
history, clinical presentation, therapies, and in-hospital
outcomes. The completeness and accuracy of patient enroll-
ment in the NRMI database and accuracy of clinical risk
factors and in-hospital events has been verified against
independent chart abstraction (8).
Outcomes within NRMI are limited to in-hospital events
as classified by NRMI investigators, without central adju-
dication. All-cause mortality was assessed in this analysis.
Stroke was defined as a permanent neurological deficit and
further classified as hemorrhagic, thromboembolic, throm-
boembolic with hemorrhagic conversion, or other (subdural
hematoma). Major bleeding was defined as bleeding requir-
ing intervention, including hemodynamic instability, trans-
fusion, or surgical intervention. Reinfarction was defined as
a second MI event confirmed by new diagnostic ECG
changes or (re)elevation of cardiac enzymes.
Statistical analyses. Our primary goal was to examine the
extent to which community use of GP IIb/IIIa inhibitors
was in accord with the ACC/AHA recommendations. A
secondary goal was to relate these observational care pat-
terns with patient outcomes. During the study period, the
ACC/AHA recommendations specified use of GP IIb/IIIa
inhibitors for “high-risk” patients (including all those
with positive cardiac markers) and in those for whom per-
cutaneous coronary intervention (PCI) was planned (2).
Because NRMI 4 does not collect information on “planned
PCI,” we defined “early treatment” as administration of
intravenous GP IIb/IIIa inhibitors within 24 h of hospital
arrival. We compared patients who received early treatment
with those not receiving early treatment (including those
never treated and those treated only after 24 h, such as
after elective PCI). This treatment comparison strategy
was conservative, as it favorably bias the no early treatment
group by including those who survived to undergo late PCI
(and received concomitant GP IIb/IIIa within the no early
treatment group).
The associations between baseline characteristics, proce-
dure use, and clinical outcomes among patients who did and
did not receive GP IIb/IIIa inhibitors within 24 h of
admission were examined using the chi-square statistic for
categorical variables and analysis of variance for continuous
variables (Table 1). A treatment-propensity analysis was
performed to identify multivariable predictors of early GP
IIb/IIIa inhibition using stepwise logistic regression analysis
(Table 2).
Several analytical techniques were used to adjust patient
Abbreviations and Acronyms
ACC  American College of Cardiology
ACE  angiotensin-converting enzyme
AHA  American Heart Association
CK  creatine kinase
GP  glycoprotein
GUSTO IV ACS  Effect of Glycoprotein IIb/IIIa
Receptor Blocker Abciximab on
Outcome in Patients with Acute
Coronary Syndromes without Early
Coronary Revascularization
MI  myocardial infarction
NRMI  National Registry of Myocardial
Infarction
NSTE  non–ST-elevation
OR  odds ratio
PCI  percutaneous coronary intervention
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outcome comparisons for potential treatment selection bi-
ases. First, we adjusted our analyses for 13 baseline clinical
risk factors using a validated NSTE MI mortality model
(Appendix) (9), C-index value in our study population
(0.75). We then sequentially adjusted our comparisons of
mortality by treatment for treatment propensity score (de-
scribed in the preceding text) and hospital features (includ-
ing geographic region, number of beds, on-site cardiac
catheterization facilities, and academic affiliation). To test
the robustness of these findings, we repeated the analyses:
1) among the subgroup of patients admitted to hospitals
with on-site PCI facilities (where patient transfer was
limited); 2) after excluding those receiving PCI within the
first 24 h; 3) after excluding all PCI patients; 4) after
excluding all patients receiving cardiac catheterization; and
5) after excluding all patients who died within the first 24 h
of admission.
We also performed a “matched pair” propensity analyses
(10,11), in which we paired patients with similar baseline
likelihood for treatment where one received early GP IIb/IIIa
treatment and one did not. After matching, analyses of baseline
characteristics were repeated to ensure that that the popula-
tions were comparable. Conditional logistic regression was
then used to determine the effect of early GP IIb/IIIa inhibi-
tion on mortality in this matched-pair sample.
Finally, the association between early GP IIb/IIIa inhi-
bition and mortality was assessed at the hospital level. For
this analysis, institutions contributing fewer than 10 pa-
tients per year (18% of the hospitals) were excluded to
ensure stable center estimates. Hospitals were subdivided
into quartiles based on the proportion of their patients with
NSTE MI who received GP IIb/IIIa inhibitors early.
Unadjusted and risk-adjusted mortality rates then were
compared among hospital subgroups. All statistical analyses
were performed using SAS software (version 8.0, SAS
Institute, Cary, North Carolina).
Table 1. Baseline Characteristics by Early Use of GP IIb/IIIa Inhibition
Characteristics
Early Use
(n  15,379)
No Early Use
(n  45,391)
Overall
(n  60,770)
Mean age (yrs) 63.0  13 72.6  14 70.2  14
Female gender 32% 48% 44%
Nonwhite race 14% 16% 15%
Insurance
Commercial/PPO 46% 19% 19%
HMO 18% 19% 19%
Medicare 42% 66% 60%
Medicaid 5% 9% 8%
VA/other 13% 9% 10%
Medical history
Prior infarction 23% 28% 26%
Diabetes mellitus 24% 32% 30%
Hypertension 57% 62% 61%
Current smoking 33% 19% 23%
Hypercholesterolemia 45% 31% 35%
Chronic lung disease 11% 13% 14%
Cerebrovascular disease 3% 5% 5%
Prior angioplasty 17% 11% 12%
Prior bypass surgery 17% 16% 16%
Admission diagnosis
Myocardial infarction 34% 21% 25%
Rule-out infarction 32% 30% 31%
Unstable angina 23% 15% 26%
Presenting symptoms
Chest pain 83% 52% 53%
Pulmonary edema 3% 9% 7%
Cardiogenic shock 1% 1% 1%
Symptoms to hospital arrival (h) 6.2  8.4 6.2  9.2 6.2  9.0
Electrocardiogram
ST depression 27% 22% 23%
T-wave inversion 18% 14% 15%
Hospital characteristics
Mean number beds 373  187 318  180 332  184
Angioplasty facility 93% 70% 76%
Bypass surgery facility 89% 66% 72%
COTH teaching hospital 15% 12% 13%
All p values  0.0001 except cardiogenic shock (p  0.90), prior bypass surgery (p  0.41), and time from symptom onset to
hospital presentation (p  0.90).
COTHCouncil Of Teaching Hospitals; GP glycoprotein; HMO health maintenance organization; PPO preferred
provider organization; VA  Veterans Affairs.
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RESULTS
Study population. The NRMI database contained
110,590 NSTE MI patients with acute MI treated at 1,189
U.S. hospitals from July 2000 to July 2001. From this, we
excluded 20,594 patients who were transferred out (19%),
5,802 patients who were transferred in more than 24 h after
hospitalization (5%), 23,038 patients with a potential con-
traindication for GP IIb/IIIa inhibition (21%), and 386
patients for whom the time when GP IIb/IIIa inhibition
began was missing (1%). This left a sample of 60,770
patients with NSTE MI who were eligible for early GP
IIb/IIIa inhibitor therapy. Of these, 15,379 patients (25%)
received such therapy within 24 h of admission. The median
time to administration of a GP IIb/IIIa agent was 6 h. The
average duration of infusion was 26.3  18 h. Among the
45,391 (75%) not receiving early GP IIb/IIIa inhibition,
4,372 (10%) received a GP IIb/IIIa blocker at some point
24 h after admission, most commonly with elective PCI.
Baseline characteristics and predictors of early treatment.
Patients receiving early GP IIb/IIIa inhibitor treatment
were significantly younger and were more likely to be white
and male and have private insurance (instead of Medicare,
Medicaid, or self-pay) (Table 1). Treated patients were less
likely to have had a prior MI or most comorbid illnesses, but
were more likely to have had a coronary revascularization
procedure. Patients who received early GP IIb/IIIa inhibitor
therapy were more likely to present with chest pain or
ST-segment depression, and were more likely to be admit-
ted with a presumed diagnosis of acute MI, compared with
patients not treated, but the time from symptom onset to
hospitalization was similar between groups. Treated pa-
tients were also more prevalent among larger hospitals,
hospitals with catheterization laboratories and bypass sur-
gery facilities, and teaching hospitals.
Table 2 displays selected independent predictors of treat-
ment in our multivariable propensity model. In total, 23
factors were independently associated with the propensity
for GP IIb/IIIa inhibitor treatment, with a model C-index
of 0.78. The factor most strongly associated with GP
IIb/IIIa inhibition was chest pain on presentation, followed
by the hospital’s capacity to perform PCI.
In-hospital care. Compared with those not treated with
early GP IIb/IIIa inhibition, treated patients were signifi-
cantly more likely to have a cardiology consultation (96% vs.
79%, p  0.0001) and to undergo in-hospital PCI (45% vs.
15%, p  0.0001). In contrast, the use of coronary bypass
surgery was similar between treated and untreated patients
(11% for each). Within 24 h of hospital admission, patients
who received early GP IIb/IIIa blockade were also more
likely to receive aspirin (91% vs. 80%, p  0.004) and
beta-blockers (75% vs. 60%, p  0.001).
In-hospital outcomes. The overall in-hospital mortality
rate was 8.0%. Patients treated early with GP IIb/IIIa
inhibitors had significantly lower unadjusted mortality than
did patients not receiving such therapy (3.3% vs. 9.6%, p 
0.001). Likewise, the rates of death or (re)MI were lower in
those receiving early therapy versus not (4.5% vs. 10.3%,
p  0.001). Unadjusted rates for nonfatal complications
of MI (shock, cardiac arrest, reinfarction) were similar or
higher in those receiving a GP IIb/IIIa inhibitor versus not.
In terms of safety, patients receiving a GP IIb/IIIa inhibitor
had a higher rate of major bleeding (10% vs. 9.5%, p 
0.04), but a lower risk for stroke (0.7% vs. 1.2%, p  0.001)
and a similar hemorrhagic stroke rate (0.1% vs. 0.1%, p 
0.38) (Table 3).
Figure 1 shows the in-hospital mortality rate for patients
treated versus not with an early GP IIb/IIIa inhibitor
stratified by NSTE MI risk score. Among all risk strata,
in-hospital mortality rates were lower in patients treated
with a GP IIb/IIIa inhibitor than in those not so treated. In
particular, the absolute treatment differences tended to be
widest among those with intermediate to high baseline risk.
Table 4 provides the results from our matched-pair
propensity analysis. After matching on treatment propen-
sity, baseline characteristics and clinical features were similar
among those treated with versus not. This matched sample
had a lower risk profile resulting in a lower overall mortality
rate than the overall study population. Despite lower risk in
this matched subset, early GP IIb/IIIa inhibitor therapy
remained associated with lower in-hospital mortality com-
pared with those not treated (3.5% vs. 3.9%, p  0.03).
Table 5 presents the mortality comparisons after sequen-
tially adjusting for baseline patient risk (NSTE MI risk
score), treatment propensity, and hospital factors. Adjust-
ment for patient risk and treatment propensity reduced the
association between early GP IIb/IIIa inhibition and in-
Table 2. Selected Predictors of Early GP IIb/IIIa Inhibitor Use
Variables Odds Ratio 95% CI
Demographics
Increasing age* 0.78 0.76–0.08
Women 0.83 0.79–0.87
Nonwhite race 0.78 0.74–0.82
Private insurance (vs. self-pay) 1.15 1.10–1.20
History
Prior percutaneous intervention 1.43 1.35–1.52
Current smoking 1.13 1.07–1.19
Diabetes mellitus 0.89 0.85–0.94
Peripheral vascular disease 0.89 0.82–0.96
Prior stroke 0.70 0.64–0.77
Chronic lung disease 0.79 0.74–0.84
Presenting patient factors
Chest pain presentation 2.28 2.21–2.39
Killip class IV 1.63 1.21–2.20
Hospital factors
Performs catheterization 1.62 1.40–1.87
Performs percutaneous interventions 2.92 2.70–3.17
*Per 10-U increase. Other variables associated with higher treatment likelihood
include family history of coronary disease, history of hyperlipidemia, ischemic
symptoms at baseline, higher presenting blood pressure, and prehospital electrocar-
diogram obtained. Other factors associated with lower treatment likelihood include
history of congestive heart failure, prior myocardial infarction, history of hypertension,
and faster presenting heart rate. C-index for model  0.780.
CI  confidence interval; GP  glycoprotein.
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hospital mortality. Further adjustment for provider factors
(hospital location, facilities, and academic affiliation) and
the use of acute therapies (aspirin and beta-blocker use
within 24 h) had limited impact on these conclusions. After
full adjustment, patients receiving a GP IIb/IIIa inhibitor
early remained significantly less likely to die compared with
those not treated (adjusted odds ratio [OR], 0.88; 95%
confidence interval [CI], 0.79 to 0.97).
This risk-adjusted analysis was repeated among impor-
tant patient subsets. The mortality reductions associated
with early GP IIb/IIIa use were similar magnitude in men
and women after adjusting for baseline risk and treatment
propensity, mortality OR in males 0.85 (0.73 to 0.97) versus
mortality OR in females 0.88 (0.74 to 1.01). Among NRMI
hospitals with on-site PCI facilities, the use of early GP
IIb/IIIa inhibitor therapy was significantly associated with
lower patient mortality (OR, 0.82 [95% CI, 0.73 to 0.92]).
Similar survival benefits of early GP IIb/IIIa inhibition also
were seen after excluding those receiving PCI within 24 h
(OR, 0.82 [95% CI, 0.73 to 0.93]) and after excluding all
patients receiving PCI at any time (OR, 0.85 [95% CI, 0.76
to 0.95]) or after excluding all patients receiving cardiac
catheterization (OR, 0.68 [95% CI, 0.60 to 0.78]). Exclud-
ing all patients who died within the first 24 h of hospital-
ization reduced the overall mortality rate by 14%, yet
patients receiving early GP IIb/IIIa treatment still tended to
have a lower in-hospital mortality risk than those not
treated (OR, 0.91 [95% CI, 0.83 to 1.01].
Figure 2 displays the association between hospitals’ use of
early GP IIb/IIIa inhibitors in patients with NSTE MI and
their overall unadjusted and risk-adjusted mortality rates.
Centers with the highest rate use of early GP IIb/IIIa (used
Table 3. In-Hospital Events by Early Use of GP IIb/IIIa Inhibitor
Early Use
(n  15,379)
No Early Use
(n  45,391)
Overall
(n  60,770) p Value
Outcomes
In-hospital mortality 3.3% 9.6% 8.0%  0.0001
Cardiogenic shock 2.7% 2.6% 2.6% 0.505
Sustained VT/VF arrest 3.6% 3.2% 3.3%  0.019
Reinfarction 1.5% 1.1% 1.2% 0.001
Death or reinfarction 4.5% 10.3% 8.8%  0.001
Stroke 0.7% 1.2% 1.1%  0.0001
Hemorrhagic stroke 0.1% 0.1% 0.1% 0.12
Major bleeding 10.0% 9.5% 9.6% 0.038
Blood transfusion 8.5% 8.7% 8.6% 0.15
Mean length of stay (days) 5.0  4.4 6.5  5.9 6.1  5.6  0.0001
GP  glycoprotein; VT/VF  ventricular fibrillation/ventricular tachycardia.
Figure 1. In-hospital mortality for patients treated with a glycoprotein (GP) IIb/IIIa inhibitor versus those not treated, by the National Registry of
Myocardial Infarction non–ST-elevation myocardial infarction (NRMI-NSTEMI) risk score.
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in 30% to 85% of patients) had nearly 50% lower unadjusted
and risk-adjusted mortality rates compared with the lowest
quartile of use. This hospital-level relationship likely results
from multiple factors including other processes of care and
structural features beyond purely the effects of GP IIb/IIIa
treatment. Regardless, adoption of this newer NSTE MI
care process appears to be good marker for overall hospital
outcomes and quality.
DISCUSSION
This study represents the first nationwide assessment of the
contemporary use of GP IIb/IIIa inhibitors in patients with
NSTE MI. Despite published randomized trials and na-
tional guideline recommendations, we found that three of
four eligible NSTE MI patients failed to receive GP
IIb/IIIa inhibitor therapy within 24 h of admission. When
studied in a higher-risk, community-based population, the
early use of GP IIb/IIIa inhibition appears generally safe
and was associated with a reduction in mortality risk similar
to that seen in randomized studies.
Randomized clinical trials have evaluated the efficacy of
GP IIb/IIIa inhibitors in more than 30,000 patients with
acute coronary syndromes (4,12). The trial populations,
however, were younger and had overall lower risk than the
patients in our community-based NRMI cohort. For exam-
ple, the mean age of patients enrolled in the three largest
trials of these agents (13–15) ranged from 61 to 64 years (vs.
70 years in NRMI). These and other differences led to
significantly higher in-hospital mortality rate in our study
patients relative to trial populations (8% in NRMI vs. 1.5%
to 3% in trials).
Areas for improvement in performance. While we found
overall low use of early GP IIb/IIIa inhibitor therapy, this
was more profound in certain groups. Older patients,
women, minorities, and those without private insurance all
were significantly less likely to receive early GP IIb/IIIa
inhibition than were their counterparts. Disparity in the use
of evidence-based care by age, gender, and socioeconomic
status is disturbing, yet it is consistently seen in many areas
of healthcare (16–19). Patients with higher baseline risk
were also paradoxically less likely to receive early GP
IIb/IIIa inhibitor treatment. For example, whereas 45% of
low-risk patients (expected risk  2%) received early GP
IIb/IIIa inhibition, only 9% of the high-risk patients (ex-
pected mortality 15%) received treatment. This pattern of
conservative care in high-risk patients is also seen in other
areas of medicine (20,21), but is inconsistent with maximiz-
ing absolute benefits from therapy (Fig. 1). It is, therefore,
incumbent upon physicians to use available risk assessment
tools to guide care decisions (22–24).
Finally, patients were more likely to receive a GP IIb/IIIa
inhibitor if they were treated at larger centers, centers with
academic affiliations or with interventional capability, or if
cared for by cardiologists. Combined, these patterns appear
to indicate that randomized studies of GP IIb/IIIa inhibi-
tion and the resultant ACC/AHA treatment recommenda-
Table 4. Baseline Characteristics and Outcomes for Matched Propensity Sample
Characteristics
Early Use
(n  14,151)
No Early Use
(n  14,151) p Value
Mean age (yrs) 63.9  13 63.9  14 0.78
Female gender 33% 33% 0.22
Nonwhite race 15% 15% 0.93
Commercial payor/PPO 45% 44% 0.30
Prior infarction 23% 24% 0.12
Diabetes mellitus 25% 26% 0.13
Hypertension 57% 57% 0.91
Hypercholesterolemia 44% 44% 0.57
Congestive heart failure 7% 7% 0.75
Chronic lung disease 11% 12% 0.60
Prior angioplasty 17% 17% 0.32
Hospital performs percutaneous
interventions
92% 92% 0.20
Teaching hospital 15% 15% 0.45
Prior bypass surgery 17% 17% 0.33
In-hospital mortality 3.5% 3.9% 0.03
PPO  preferred provider organization.
Table 5. Association of Early GP IIb/IIIa Inhibitor Use and In-Hospital Mortality
Models Odds Ratio* 95% CI C-Index
Unadjusted 0.32 0.30–0.36 0.58
Adjusted for clinical risk factors 0.61 0.58–0.68 0.75
Plus treatment propensity 0.88 0.79–0.98 0.76
Plus propensity and hospital factors 0.88 0.79–0.97 0.76
*For early use of GP IIb/IIIa inhibitor versus no early use.
CI  confidence interval; GP  glycoprotein.
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tions have yet to diffuse to all healthcare providers and
specialties.
Safety and effectiveness of GP IIb/IIIa inhibition.
While being observational in nature, this study also provides
insight into the safety, effectiveness, and appropriate timing
of GP IIb/IIIa inhibition in “real-world” patients. Although
the NRMI cohort was older and higher risk than prior trial
populations, we found a 1% absolute increase in the risk
of major bleeding and no increased risk of stroke or
intracranial hemorrhage associated with GP IIb/IIIa
inhibition.
With regard to effectiveness, early GP IIb/IIIa therapy
was associated with significantly lower in-hospital mortality
rates, an effect that persisted after adjustment for patient
and provider factors and treatment selection (Table 5). The
plausibility of this finding is increased by its robustness. The
estimated benefit of GP IIb/IIIa inhibition was constant
across an array of risk-adjustment techniques and patient
subgroups. The magnitude of mortality benefit also was
remarkably consistent with those estimated from a meta-
analysis of the major GP IIb/IIIa inhibitor trials (4). In an
overview of the major GP IIb/IIIa inhibitor trials, the
30-day mortality risk reduction with treatment was 0.87
(95% CI, 0.74 to 1.02) (25) versus the current study
estimate of 0.88 (95% CI, 0.79 to 0.97). Our larger patient
population and higher event rates, however, provided
greater statistical power to detect a significant association
between early treatment and lower mortality.
The interrelation between the benefits of GP IIb/IIIa
therapy and interventional strategies deserve further com-
ment. In our study, patients receiving early GP IIb/IIIa
therapy were significantly more likely to receive cardiac
catheterization and PCI than those not, raising the possi-
bility that the benefits demonstrated were related to the
combination of early GP IIb/IIIa therapy and PCI. In fact,
this combined aggressive, interventional strategy is sup-
ported by the recent Treat Angina with Aggrastat and
Determine Cost of Therapy with an Invasive or Conserva-
tive Strategy (TACTICS-TIMI 18) randomized trial and
has been incorporated into subsequent ACC/AHA guide-
lines recommendations.
A related question is whether the benefits from early GP
IIb/IIIa inhibitor therapy are limited only to those receiving
an interventional approach. This possibility was raised by
the negative results of the Effect of Glycoprotein IIb/IIIa
Receptor Blocker Abciximab on Outcome in Patients with
Acute Coronary Syndromes without Early Coronary Revas-
cularization (GUSTO IV ACS) when a GP IIb/IIIa was
tested in a predominately conservatively treated ACS pop-
ulation (13). However, a subgroup analysis from the six
major GP IIb/IIIa trials (including GUSTO IV ACS)
reported that both PCI patients and non-PCI patients had
trends towards mortality benefits with GP IIb/IIIa therapy
OR 0.83 (0.53 to 1.29) and 0.91 (0.81 to 1.04), respectively
(12). Our current observational analysis was consistent with
this trial overview finding that the benefits of early GP
IIb/IIIa therapy persisted after excluding those who had
PCI or cardiac catheterization. While intriguing, further
Figure 2. Unadjusted and risk-adjusted in-hospital mortality for patients with non–ST-elevation myocardial infarction (NSTEMI), by the proportion of
NSTEMI patients at each hospital treated early with a glycoprotein (GP) IIb/IIIa inhibitor.
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study of the potential benefits of GP IIb/IIIa therapy among
medically treated patients appears warranted.
With regard to nonfatal events, our study was not able to
replicate trial findings of a reduction in reinfarction with GP
IIb/IIIa therapy. There are several potential reasons for this.
Most important, our NSTE MI population could not assess
the benefits of prevention of infarction in those with
unstable angina, only assessing “re-infarction.” This end
point is difficult to measure in registries due to inconsistency
in drawing sequential cardiac markers and the lack of central
event adjudication. As a result, the reported rate of rein-
farction in NRMI’s higher risk patients was less than half
the rate in randomized trials.
Study limitations. This study was based on a voluntary
registry of MI care at 1,000 U.S. centers. Although this
represents about 25% of U.S. hospitals, participating hos-
pitals tend to be larger and have more interventional
facilities compared with non-NRMI hospitals. Thus, our
reported results likely underestimate the current gap be-
tween clinical practice and guideline-recommended treat-
ment. Contraindications to GP IIb/IIIa agents were based
on chart review, which may lead to under-coding. However,
we doubt that this can fully explain the three-fourths of
patients not receiving treatment.
Our treatment comparisons were based on observational
data and are subject to the limitations of all nonrandom-
ized analyses. Although we applied multiple techniques to
adjust for potential patient and provider differences, we
acknowledge that unmeasured treatment-selection biases
could persist. Issues of early mortality may further compli-
cate treatment comparison. However, the relative benefits
of GP IIb/IIIa therapy tended to persist after conserva-
tively excluding patients who died within 24 h. Finally, as
discussed above, outcome differences both at the patient
and provider levels (Fig. 2) may have resulted from the
effects of care other than GP IIb/IIIa inhibitor therapy.
Although the benefits of GP IIb/IIIa inhibition persisted
after adjustment for other acute therapies (acute PCI,
aspirin, and beta-blockers), fully adjusting for downstream
management differences is challenging due to survivor bias
issues.
Conclusions. This study shows that the safety and efficacy
of early GP IIb/IIIa inhibition in patients with NSTE MI
appear to be generalizable to a national sample. Importantly,
despite ACC/AHA care guidelines, we found these agents
were underused, particularly in high-risk patient subgroups.
We hope that ongoing provider feedback and quality-
improvement programs will help hasten the dissemination
and adoption of guideline recommendations into clinical
practice (6,26–28).
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APPENDIX
NRMI-NSTE MI Risk Model (9)
Risk Factors Points
Age 65 yrs 3
Female gender (65 yrs) 1
Admission diagnosis not unstable angina 2
ST-segment depression on admission 1
Systolic blood pressure 120 mm Hg or
heart rate 100 beats/min
2
Killip class I 1
History of renal insufficiency 1
History of congestive heart failure 1
History of chronic lung disease 1
No history of hypercholesterolemia 1
No history of hypertension 1
No current smoking 1
No previous percutaneous intervention 1
NRMI  National Registry of Myocardial Infarction; NSTE  non–ST-elevation;
MI  myocardial infarction.
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